REGN Shareholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors Class Action Against Regeneron Pharmaceuticals, Inc.
January 13, 2025 21:48 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that Regeneron Pharmaceuticals, Inc. (REGN) Misled Investors Regarding its Business Prospects
Stockholder Notice: Robbins LLP Informs Stockholders of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit
January 08, 2025 18:38 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that Regeneron Pharmaceuticals, Inc. (REGN) Misled Investors Regarding its Business Prospects
Robbins LLP Reminds Investors of the Pending Class Action Against Cassava Sciences, Inc. and Urges SAVA Stockholders to Contact the Firm for Information
January 06, 2025 20:26 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that Cassava Sciences, Inc. (SAVA) Misled Investors Regarding its Lead Drug Candidate
HUMA Lead Plaintiff Deadline Approaching – Contact Robbins LLP for Information About the Class Action Against Humacyte, Inc.
December 24, 2024 15:58 ET
|
Robbins LLP
Robbins LLP is Investigating Allegations that Humacyte, Inc (HUMA) Misled Investors Regarding its Manufacturing Practices.
CBIH Strengthens Clinical Research Team in Preparation for Launch of Next-Generation Cannabinoid Solutions
November 18, 2024 08:00 ET
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) continues to invest in top-tier talent as it prepares to launch its specialized pharmaceutical a
Cannabis Bioscience International Holdings Selected to Participate in DEA Hearing on Cannabis Rescheduling Docket No. 1362 and Hearing Docket No. 24-44
November 12, 2024 08:00 ET
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is honored to announce it was selected from a competitive field of numerous companies as one of
HiberCell Receives FDA Fast Track Designation for HC-7366 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
October 23, 2024 10:30 ET
|
HiberCell, Inc.
BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce...
Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate CBX-12 in Phase 2 Trial in Ovarian Cancer
October 07, 2024 07:00 ET
|
Cybrexa Therapeutics
Cybrexa announces the first patient has been dosed in a Ph2 clinical trial evaluating CBX-12 in women with platinum-resistant or refractory ovarian cancer.
CBIH Announces Strategic Advancements Initiated by Recently Appointed Director, Setting a New Paradigm and Driving Visionary Change
June 26, 2024 10:52 ET
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
As CBIH prepares for the manufacturing and distribution of its products, the potential collaboration might involve this entity acting as CBIH's distributor
Unleashing the Potential of Cannabis: Cannabis Bioscience International Holdings Reaches a Historic Valuation
June 17, 2024 09:50 ET
|
CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.
CBIH a company dedicated to medicinal cannabis research for over 15 years, has achieved a 2 billion dollar valuation.